ClinicalTrials.gg
CompletedNCT00377819Updated Jul 11, 2011Results posted

Study of Transitioning From Alendronate to Denosumab

A Phase 3 interventional study of alendronate and Denosumab (AMG 162) in Postmenopausal Osteoporosis, sponsored by Amgen. Completed. Open to female participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2011-07-11.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
504
Allocation
Randomized
Ages
55 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.

Enrollment
7th of 31
504 · median 278
Started
2006
with 1 other
Phase 3
17 of 31
1 open now
Registered
4th of 31
by date
Lead sponsor
12 of 31
Amgen

Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 7th largest by enrollment, is one of 2 that started in 2006, is one of 17 in phase 3, and was the 4th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 55 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing denosumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

The study will evaluate the efficacy and safety of transitioning postmenopausal women on current alendronate therapy to denosumab. Endpoints studied will include bone mineral density, bone turnover markers and bone histology in a subset of subjects.

03

Conditions studied

  • Postmenopausal Osteoporosis

Keywords

  • RANKL
  • RANK
  • denosumab
  • AMG 162
  • osteoporosis
  • bone turnover
  • bone mineral density
  • clinical trial
  • postmenopausal osteoporosis
  • alendronate
  • total hip bone mineral density
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • females 55 yrs or older
  • Received alendronate therapy for osteoporosis for at least 6 months prior to entry into study
  • Lumbar spine or total hip Bone Mineral Density (BMD) corresponding to T-score ≤ -2 and ≥ -4

Exclusion criteria

Exclusion Criteria:

  • Vitamin D deficiency
  • Administration of intravenous bisphosphonate, or
  • fluoride (except for dental treatment) or
  • strontium ranelate
  • Administration of Parathyroid Hormone (PTH) or Parathyroid Hormone (PTH) derivatives (eg; teriparatide) within the last year
  • Administration of any bisphosphonate other than alendronate (ALN) within 1 year of screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
504 participants (actual)

Study arms

  • Experimental
    denosumab

    Drug: Denosumab (AMG 162)

  • Active comparator
    alendronate

    Drug: alendronate

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Total Hip Bone Mineral Density

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using \[(12 month value - baseline value) / baseline value\]\*100.

    Time frame: Baseline, 12 months

Secondary outcomes

  1. Percent Change From Baseline in Lumbar Spine Bone Mineral Density

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using \[(12 month value - baseline value) / baseline value\]\*100.

    Time frame: Baseline, 12 months

  2. Percent Change From Baseline in Serum C-Telopeptide-I (CTX-I)

    Percent Change From Baseline to Month 3 in Serum CTX-I. Percent change calculated using \[(3 month value - baseline value) / baseline value\]\*100.

    Time frame: Baseline, 3 months

07

Results

Posted Aug 3, 2010

Participant flow

First Subject Enrolled: 02-Oct-2006 Last Subject Enrolled: 07-Mar-2007

Participant flow — Overall Study
MilestoneAlendronate 70 mg QWDenosumab 60 mg Q6M
Started251253
Received study medication249253
Completed238243
Not completed1310
Withdrew: Adverse event23
Withdrew: Withdrawal by subject104
Withdrew: Death01
Withdrew: Lost to follow-up01
Withdrew: Protocol violation11

Outcome measures

PrimaryPercent Change From Baseline in Total Hip Bone Mineral Density

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using \[(12 month value - baseline value) / baseline value\]\*100.

Time frame:
Baseline, 12 months
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Total Hip Bone Mineral Density
Percent ChangeAlendronate 70 mg QWDenosumab 60 mg Q6M
Percent Change From Baseline in Total Hip Bone Mineral Density1.05 (0.76 to 1.34)1.9 (1.61 to 2.18)
Statistical analysis
  • Alendronate 70 mg QW vs Denosumab 60 mg Q6M · Repeated Measures Model · p = <0.0001 · Mean difference (final values): 0.85 · 95% CI 0.44 to 1.25Based on repeated measures model adjusting for treatment, length of prior alendronate stratification variable, visit, baseline value, machine type, treatment by visit interaction, and baseline value by machine type interaction
SecondaryPercent Change From Baseline in Lumbar Spine Bone Mineral Density

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry. Percent change calculated using \[(12 month value - baseline value) / baseline value\]\*100.

Time frame:
Baseline, 12 months
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Lumbar Spine Bone Mineral Density
Percent ChangeAlendronate 70 mg QWDenosumab 60 mg Q6M
Percent Change From Baseline in Lumbar Spine Bone Mineral Density1.85 (1.44 to 2.26)3.03 (2.63 to 3.44)
Statistical analysis
  • Alendronate 70 mg QW vs Denosumab 60 mg Q6M · Repeated Measures Model · p = <0.0001 · Mean difference (final values): 1.18 · 95% CI 0.63 to 1.73Based on repeated measures model adjusting for treatment, length of prior alendronate stratification variable, visit, baseline value, machine type, treatment by visit interaction, and baseline value by machine type interaction
SecondaryPercent Change From Baseline in Serum C-Telopeptide-I (CTX-I)

Percent Change From Baseline to Month 3 in Serum CTX-I. Percent change calculated using \[(3 month value - baseline value) / baseline value\]\*100.

Time frame:
Baseline, 3 months
Reported as:
Median · Percent Change
Percent Change From Baseline in Serum C-Telopeptide-I (CTX-I)
Percent ChangeAlendronate 70 mg QWDenosumab 60 mg Q6M
Percent Change From Baseline in Serum C-Telopeptide-I (CTX-I)-4.2 (-29.4 to 25.1)-63.3 (-78.5 to -38.0)
Statistical analysis
  • Alendronate 70 mg QW vs Denosumab 60 mg Q6M · Van Elteren Stratified Rank Test · p = <0.0001

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alendronate 70 mg QW—16/249 (6.4%)101/249 (40.6%)
Denosumab 60 mg Q6M—15/253 (5.9%)103/253 (40.7%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventAlendronate 70 mg QWDenosumab 60 mg Q6M
Tooth fractureInjury, poisoning and procedural complications2/2490/253
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/2490/253
Angina pectorisCardiac disorders1/2491/253
Atrial fibrillationCardiac disorders1/2490/253
Appendicitis perforatedGastrointestinal disorders1/2490/253
Loose toothGastrointestinal disorders1/2490/253
NauseaGastrointestinal disorders1/2490/253
PancreatitisGastrointestinal disorders1/2490/253
VomitingGastrointestinal disorders1/2490/253
HyperpyrexiaGeneral disorders1/2490/253
Most frequent other events
Most frequent other events
EventAlendronate 70 mg QWDenosumab 60 mg Q6M
NasopharyngitisInfections and infestations27/24934/253
Back painMusculoskeletal and connective tissue disorders29/24927/253
ArthralgiaMusculoskeletal and connective tissue disorders26/24915/253
Pain in extremityMusculoskeletal and connective tissue disorders21/24912/253
BronchitisInfections and infestations14/24916/253
OsteoarthritisMusculoskeletal and connective tissue disorders13/24911/253
ConstipationGastrointestinal disorders12/24913/253

Baseline characteristics

Age Continuous
Age Continuous(Years)Alendronate 70 mg QWDenosumab 60 mg Q6MTotal
Mean68.2 ± 7.766.9 ± 7.867.6 ± 7.8
Sex: Female, Male
Sex: Female, Male(Participants)Alendronate 70 mg QWDenosumab 60 mg Q6MTotal
Female251253504
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Alendronate 70 mg QWDenosumab 60 mg Q6MTotal
White or Caucasian232238470
Black or African American202
Hispanic or Latino121123
Asian112
Japanese134
American Indian or Alaska Native101
Native Hawaiian or Other Pacific Islander101
Other101
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010 Jan;25(1):72-81. doi: 10.1359/jbmr.090716. PubMed 19594293 ↗
  • Miller PD, Pannacciulli N, Malouf-Sierra J, Singer A, Czerwinski E, Bone HG, Wang C, Huang S, Chines A, Lems W, Brown JP. Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates. Osteoporos Int. 2020 Jan;31(1):181-191. doi: 10.1007/s00198-019-05233-x. Epub 2019 Nov 28. PubMed 31776637 ↗
  • Gold DT, Horne R, Coon CD, Price MA, Borenstein J, Varon SF, Satram-Hoang S, Macarios D. Development, reliability, and validity of a new Preference and Satisfaction Questionnaire. Value Health. 2011 Dec;14(8):1109-16. doi: 10.1016/j.jval.2011.06.010. Epub 2011 Oct 1. PubMed 22152181 ↗
  • Reid IR, Miller PD, Brown JP, Kendler DL, Fahrleitner-Pammer A, Valter I, Maasalu K, Bolognese MA, Woodson G, Bone H, Ding B, Wagman RB, San Martin J, Ominsky MS, Dempster DW; Denosumab Phase 3 Bone Histology Study Group. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res. 2010 Oct;25(10):2256-65. doi: 10.1002/jbmr.149. PubMed 20533525 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Mar 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2010, 2 years 5 months after primary completion. A results delay was requested in Nov 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2006
First posted
Sep 18, 2006
Start
Sep 2006
Primary completionActual
Mar 2008
CompletionActual
Jul 2008
Results delay requested
Nov 19, 2009
Results first posted
Aug 3, 2010
Last update
Jul 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00377819
Lead sponsor
Amgen
First posted
Sep 18, 2006
Start date
Sep 2006
Primary completion
Mar 2008
Completion
Jul 2008
Results posted
Aug 3, 2010
Last update
Jul 11, 2011

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion